you are here: HomeNewsTrendsHealth

GSK, Sanofi begin new COVID-19 vaccine trial after setback last year

The move comes after the drugmakers in December said their vaccine would be delayed after clinical trials showed an insufficient immune response in older people.

February 22, 2021 / 05:46 PM IST

Britain's GlaxoSmithKline and France's Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate and aim to reach the final testing stage in the second quarter.

If the results are conclusive, the two drugmakers hope to see the vaccine approved by the fourth quarter after having initially targeted the first half of this year.

The move comes after the drugmakers in December said their vaccine would be delayed after clinical trials showed an insufficient immune response in older people.

Follow our LIVE blog for latest updates of the novel coronavirus pandemic

The new trial will aim at evaluating the safety, tolerability and immune response of the vaccine in 720 healthy adults across the United States, Honduras and Panama, the companies said.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Sanofi and GSK's candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines. It will be coupled with an adjuvant, a substance that acts as a booster to the shot, made by GSK.

The study will test two injections given 21 days apart.

Follow our full coverage of the coronavirus pandemic here.
Reuters
first published: Feb 22, 2021 05:41 pm

stay updated

Get Daily News on your Browser
Sections